92470-27-4

Upstream product

• 50-00-0 formaldehyd 
• 64-18-6 formic acid 
• 161193-44-8 C₃₇H₆₆N₂O₁₂ 
• 76801-85-9 9-Deoxo-9a-aza-9a-homoerythromycin A 
• 7704-67-8 erythromycin thiocyanate A 
• 13127-18-9 (9-E)-deoxo-9-hydroximinoerythromycin A 
• 1148112-37-1 C₂₃H₃₂O₃Si 
• 1199944-13-2 C₃₀H₃₆O₄Si 
• 1148112-26-8 C₃₀H₃₈O₅Si 
• 1148112-25-7 C₂₃H₃₄O₄Si 
• 1199945-27-1 C₁₄H₃₃NO₃Si 
• 1148112-15-5 C₂₀H₄₇NO₃Si₂ 
• 1148112-35-9 C₂₀H₄₅N₃O₃Si₂ 
• 1148112-33-7 C₅₀H₁₀₀N₂O₁₂Si₂ 

Downstream Products

• 592476-49-8 carbonic acid benzyl ester 4-dimethylamino-2-[2-ethyl-3,4,10-trihydroxy-13-(4-methoxy-4,6-dimethyl-5-oxo-tetrahydro-pyran-2-yloxy)-3,5,6,8,10,12,14-heptamethyl-15-oxo-1-oxa-6-aza-cyclopentadec-11-yloxy]-6-methyl-tetrahydro-pyran-3-yl ester 
• 90503-06-3 azithromycin-3'-N-oxide 
• 172617-84-4 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)‐2‐ethyl‐3,4,10‐trihydroxy‐13‐{(2R,4R,5S,6S)‐5‐hydroxy‐4‐methoxy‐4,6‐dimethyl-tetrahydropyran‐2‐yloxy}‐11‐{(2S,3R,4S,6R)‐3‐hydroxy‐6‐methyl‐4‐methylamino-tetrahydropyran‐2‐yloxy}‐3,5,6,8,10,12,14‐heptamethyl‐1‐oxa‐6‐azacyclopentadecan‐15‐one 
• 3758-45-0 cladinose 
• 117693-41-1 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)‐11-((2S,3R,4S,6R)‐4-dimethylamino-3-hydroxy-6-methyl-tetrahydropyran-2-yloxy)-2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopetadecan-15-one 

Relevant academic research and scientific papers

Preparation method of azithromycin (by machine translation)

After the reaction temperature is, the reaction temperature of A is adjusted 0 °C to, for NaHCO3 hours, and then the reaction solution is evaporated and dried, 1 by suction filtration, at NaOH. degree. C. for PH hours to obtain a white solid 11 - 12, which is dissolved in an ethanol solution 3 and subjected to suction filtration to obtain a white solid . The invention discloses a 2h preparation method, of azithromycin in an ethanol solution after reaction, A; hours to carry out suction filtration; to A g of the toluene, sulfonyl. chloride, obtained 10 °C. (by machine translation)

Mild, calcium catalysed Beckmann rearrangements

A mild calcium catalysed Beckmann rearrangement has been realised, which forgoes the more traditional harsh reactions conditions associated with the transformation. The catalyst system is shown to be tolerant towards a wide variety of functional groups relevant to natural product synthesis and medicinal chemistry and the synthetic utility of the reaction has also been investigated. A preliminary mechanistic investigation was performed to understand the nature of the incoming nucleophile and a possible reaction pathway is described.

NOVEL ANTI-INFECTIVE AND ANTI-INFLAMMATORY COMPOUNDS

Lysosomally accumulated substances that release a nitroxy group, or a short chain fatty acid or a product of anaerobic metabolism or a thiol or a sulfide often from an ester or similar labile linkage have anti-inflammatory, anti-cancer and anti-bacterial activity. They are useful in treating infectious, inflammatory and malignant disease.

Preparation method of norazithromycin

The invention discloses a preparation method of norazithromycin and relates to the technical field of macrolide antibiotics. The preparation method comprises the following steps: reducing erythrocin A 6,9-imino ether in water at 0 DEG C to room temperature under the pH of 7.0-9.0 by using a reducing agent sodium borohydride or potassium borohydride; then in the presence of an organic solvent and water, performing continuous hydrolysis at 0 DEG C to room temperature under the pH of 2.0-3.0; then adding two-phase reaction liquids after continuous hydrolysis into an alkaline aqueous solution, adjusting the pH to be greater than or equal to 12, stirring, layering and abandoning the aqueous phase, wherein the organic solvent is dichloromethane, chloroform, 1,2-dichloromethane, ethyl acetate or butyl acetate; and after the last hydrolysis reaction in continuous hydrolysis, performing layering, directly adding the aqueous phase into the alkaline aqueous solution, adjusting the pH to be greater than or equal to 12, and performing stirring and separating out norazithromycin. The method increases the utilization ratio of the reducing agent, can control reverse reactions of borate, and reduces unnecessary separating process to obtain high quality norazithromycin.

Method for synthesizing azithromycin

The invention relates to a method for synthesizing azithromycin. According to the invention, erythromycin thiocyanate is adopted as an initial raw material of an oximation reaction, such that erythromycin oxime thiocyanate is obtained; the next step of reaction is directly carried out; and through rearrangement, reduction and methylation reactions, azithromycin is obtained. The rearrangement and reduction reactions are carried out with a one-pot method. A reduction reaction product is not separated in a solid form, and is directly used in the methylation reaction. With the synthesizing method provided by the invention, a conversion process from erythromycin oxime thiocyanate to eythromycin oxime is eliminated, and steps that rearrangement and reduction products are separated in solid forms in an original process are also eliminated. The process is environment-friendly and simple, and has the advantages of high yield, low cost, low pollution and high product purity. The method is suitable for industrialized productions.

AZITHROMYCIN ANTIMICROBIAL DERIVATIVES WITH NON-ANTIBIOTIC PHARMACEUTICAL EFFECT

The invention provides molecules, which are based on a modification of azithromycin, removing the antibiotic effect, while retaining other beneficial effects, such as, but not limited to imunomodulatory effects. The compounds of the invention can be described by compounds of Formula (I) as further defined herein.

PROCESS FOR THE PURIFICATION OF AZITHROMYCIN BY SEPARATION FROM ITS THERMAL DEGRADATION PRODUCTS AND/OR ISOMERS

The present invention relates to methods for improving the purity of azithromycin, preferably by purifying azithromycin from degradation products and/or isomers. The invention describes a degradation product of azithromycin which may be produced during drying and/or storage of azithromycin and relates to methods of removing the degradation product(s). The invention further relates to a method for preparing azithromycin dihydrate from crude azithromycin containing the isomer azithromycin B. The invention furthermore relates to a combined process for making azithromycin dihydrate which combines the method for the purification of azithromycin from degradation products with the method for making azithromycin dihydrate which removes the isomer azithromycin B.

COATED PELLETS

Coated pellets which comprise an active pharmaceutical ingredient that is poorly soluble in water, release at least 80% of the active ingredient under in vitro conditions in phosphate buffer at pH 5.0 after 30 minutes and are bioequivalent to a liquid formulation of the active ingredient under in vitro fed status test conditions and/orare coated with a composition, which includes a lipophilic component (A) and a hydrogel former (B), wherein the pure lipophilic component (A) has (i) an HLB value of ≦5, and/or(ii) a melting range of ≧60° C, and/or(iii) a solidification range Δ of less than 35° C., and/or(iv) a density of ≧0.80 g cm?3.

A COST EFFECTIVE PROCESS FOR PREPARING 6,9-IMINO ETHER

The present invention relates to an improved process for the preparation of 6,9-imino ether of formula (I) an intermediate used in preparation of Azithromycin. The present invention further provides a process for preparation of Azithromycin.

Total synthesis of azithromycin

The quaternary king: Azithromycin (1), which has improved pharmacological profiles compared with erythromycins, was the target of an enantioselective synthesis. All the stereogenic quaternary carbon centers were elaborated by a desymmetrization of 2-subst